scispace - formally typeset
E

Eric J. Topol

Researcher at Scripps Health

Publications -  1406
Citations -  162373

Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.

Papers
More filters
Journal ArticleDOI

The Myth of the Myocardial ‘Infarctlet’ During Percutaneous Coronary Revascularization Procedures

TL;DR: One of the most controversial issues in interventional cardiology today is whether small MIs, diagnosed by enzymatic abnormalities coincident with percutaneous coronary interventional procedures, are clinically relevant.
Journal ArticleDOI

Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience.

TL;DR: Certain groups of patients with AMI, including the elderly, women, diabetic patients, and minorities, exhibit delays to hospital arrival and treatment in the emergency setting, and patients and health care providers must be educated regarding high-risk populations for delay to maximize benefit from fibrinolytic therapy.
Journal ArticleDOI

Effects of Reteplase and Alteplase on Platelet Aggregation and Major Receptor Expression During the First 24 Hours of Acute Myocardial Infarction Treatment

TL;DR: In this article, the effects of reteplase and alteplases on platelet aggregation and major surface antigen expression during the first 24 hours of infarction therapy are unknown.
Journal ArticleDOI

Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)

TL;DR: The activated clotting time (ACT) has been used during percutaneous transluminal coronary angioplasty to monitor the extent of thrombin inhibition and anti-coagulation from heparin in an attempt to minimize untoward thrombotic events and hemorrhagic complications.